Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Assets (2016 - 2025)

Coherus Oncology's Assets history spans 13 years, with the latest figure at $258.3 million for Q4 2025.

  • For Q4 2025, Assets fell 42.4% year-over-year to $258.3 million; the TTM value through Dec 2025 reached $258.3 million, down 42.4%, while the annual FY2025 figure was $258.3 million, 42.4% down from the prior year.
  • Assets for Q4 2025 was $258.3 million at Coherus Oncology, down from $516.5 million in the prior quarter.
  • Across five years, Assets topped out at $763.5 million in Q1 2024 and bottomed at $258.3 million in Q4 2025.
  • The 5-year median for Assets is $548.5 million (2022), against an average of $554.4 million.
  • The largest annual shift saw Assets soared 89.74% in 2024 before it plummeted 51.4% in 2025.
  • A 5-year view of Assets shows it stood at $679.3 million in 2021, then dropped by 29.22% to $480.8 million in 2022, then surged by 30.94% to $629.6 million in 2023, then decreased by 28.76% to $448.5 million in 2024, then plummeted by 42.4% to $258.3 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Assets are $258.3 million (Q4 2025), $516.5 million (Q3 2025), and $439.5 million (Q2 2025).